Genmab Shares Jump After Drug Combination Cuts Death Risk by Half in Head and Neck Cancer

Phase 3 trial shows petosemtamab plus Keytruda halves risk of death versus Keytruda alone in first-line PD-L1+ recurrent/metastatic HNSCC.